公开(公告)号：US20240167031A1

公开(公告)日：2024-05-23

申请号：US18283925

申请日：2022-03-31

Applicant: Biogen MA Inc.

Inventor： Hasan M. Yildiz ,  Mandana Bornapour ,  Paul Peng ,  Vishwesh A. Patil ,  Brian R. Simler ,  William F. Kiesman

IPC: C12N15/113 ,  A61K9/00 ,  A61K9/51 ,  A61K47/59

CPC classification number: C12N15/113 ,  A61K9/0019 ,  A61K9/0085 ,  A61K9/5153 ,  A61K47/59 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/322 ,  C12N2310/3341 ,  C12N2310/335 ,  C12N2310/345

Abstract: Featured are polymeric nanocarriers (e.g., PLGA nanoparticles) with encapsulated nucleic acid (e.g., an antisense oligonucleotide) for delivery (e.g., intrathecally) to the central nervous system. These polymeric nanocarriers are useful in the treatment of central nervous system disorders. They are capable of delivering their cargo (e.g., an antisense oligonucleotide) in higher amounts, for a longer period of time, and into deeper regions of the brain than a free or unformulated antisense oligonucleotide. The efficient delivery and distribution of antisense oligonucleotides results in reducing the number of administrations and patient compliance and improves patient experience.

公开(公告)号：US20240116922A1

公开(公告)日：2024-04-11

申请号：US18269073

申请日：2021-12-21

Applicant: BIOGEN MA INC.

Inventor： Emily Anne Peterson ,  Magnus Pfaffenbach ,  Fang Gao ,  Philippe Bolduc ,  Zhili Xin ,  Ryan Evans

IPC: C07D471/04 ,  A61K45/06 ,  C07D487/04

CPC classification number: C07D471/04 ,  A61K45/06 ,  C07D487/04

Abstract: This disclosure relates to imidazo[1,2-a]pyridinyl derivatives of formula (I), or pharmaceutically acceptable salts thereof, Formula (I) in which all of the variables are as defined in the specification, capable of modulating the activity of IRAK4. The disclosure further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including inflammatory disease, autoimmune disease, cancer, cardiovascular disease, a disease of the central nervous system, disease of the skin, an ophthalmic disease and condition, and a bone disease.

公开(公告)号：US20240101971A1

公开(公告)日：2024-03-28

申请号：US18273053

申请日：2022-01-21

Applicant: Biogen MA Inc.

Inventor： Terrence Michael Dobrowsky ,  Jenny Wang-Yuanzhen Shupe

IPC: C12N7/00 ,  C12M1/00 ,  C12N15/85

CPC classification number: C12N7/00 ,  C12M29/10 ,  C12N15/85 ,  C12N2750/14122 ,  C12N2750/14123 ,  C12N2750/14152 ,  C12N2800/107

Abstract: The present disclosure pertains to methods and compositions for the production of recombinant viral vectors, e.g., recombinant adeno-associated viruses (rAAVs), using at least one microtubule destabilizing agent described herein.

公开(公告)号：US20240100155A1

公开(公告)日：2024-03-28

申请号：US18165146

申请日：2023-02-06

Applicant: BIOGEN MA INC.

Inventor： Alexey A. Lugovskoy ,  Frederick R. Taylor ,  Karen McLachlan

IPC: A61K39/395 ,  A61K45/06 ,  C07K16/28 ,  C07K16/30

CPC classification number: A61K39/39558 ,  A61K45/06 ,  C07K16/2839 ,  C07K16/2842 ,  C07K16/3061 ,  C07K2317/24 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92

Abstract: This invention relates to alpha-4 binding antibodies, and fragments thereof.

公开(公告)号：US20230406878A1

公开(公告)日：2023-12-21

申请号：US18036459

申请日：2021-11-10

Applicant: BIOGEN MA INC.

Inventor： Wuming Yan ,  Xuan Zhou ,  Xianglin Shi ,  Firoz Antia ,  William F. Kiesman ,  Yannick Fillon

IPC: C07H21/02 ,  C07F7/18 ,  C07D249/06 ,  C07D295/192 ,  C07H23/00 ,  C07H21/04

CPC classification number: C07H21/02 ,  C07F7/1804 ,  C07D249/06 ,  C07D295/192 ,  C07H23/00 ,  C07H21/04

Abstract: The present disclosure describes novel reagents and processes for preparing oligonucleotides, which have two or more nucleotides. In one embodiment, the reagent is represented by Formula I′ or B.

公开(公告)号：US11820760B2

公开(公告)日：2023-11-21

申请号：US17283301

申请日：2019-10-15

Applicant: BIOGEN MA INC.

Inventor： Fengmei Zheng ,  Anton Peterson ,  Kalyan Vasudevan ,  Chaomin Li ,  Daniel B. Patience ,  Yiqing Lin

IPC: C07D405/14

CPC classification number: C07D405/14 ,  C07B2200/13

Abstract: Provided are crystalline forms of (R)-1-(tert-butyl)-N-(8-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-2-(oxetan-3-yl)-2,3,4,5-tetrahydro-1H-benzo[c]azepin-5-yl)-1H-1,2,3-triazole-4-carboxamide, pharmaceutical compositions, methods of use and methods of making thereof.

公开(公告)号：US20230340489A1

公开(公告)日：2023-10-26

申请号：US18026772

申请日：2021-09-15

Applicant: Biogen MA Inc.

Inventor： Shih-Ching Lo ,  Alexander McCampbell ,  Maria Zavodszky ,  Edward Guilmette ,  Barret Pfeiffer

IPC: C12N15/113 ,  C12N15/86 ,  A61P25/28 ,  A61K48/00

CPC classification number: C12N15/1137 ,  C12N15/86 ,  A61P25/28 ,  A61K48/0058 ,  C12Y115/01001

Abstract: The present disclosure provides compositions and methods for treating amyotrophic lateral sclerosis (ALS). Among other things, the present disclosure provides inhibitory nucleic acids that inhibit the expression of genes that cause or are implicated in ALS pathogenesis. The present disclosure further provides recombinant adeno-associated virus (rAAV) vectors comprising inhibitory nucleic acids that inhibit the expression of genes that cause or are implicated in ALS pathogenesis.

公开(公告)号：US20230337967A1

公开(公告)日：2023-10-26

申请号：US18210489

申请日：2023-06-15

Applicant: Biogen MA Inc.

Inventor： Donald R. Johns ,  Dawei [b2047] Liu ,  Toby Ferguson ,  Jesse M. Cedarbaum

IPC: A61B5/00 ,  A61B5/11 ,  A61B5/145 ,  A61B5/22 ,  A61B5/24 ,  A61B5/389

CPC classification number: A61B5/4519 ,  A61B5/1123 ,  A61B5/1121 ,  A61B5/4842 ,  A61B5/4571 ,  A61B5/7246 ,  A61B5/4585 ,  A61B5/4595 ,  A61B5/4576 ,  A61B5/458 ,  A61B5/459 ,  A61B5/4848 ,  A61B5/14546 ,  A61B5/224 ,  A61B5/14542 ,  A61B5/24 ,  A61B5/389

Abstract: Methods for evaluating subjects having conditions associated with loss of muscle function (e.g., a motor neuron disease, a neuromuscular disease, or a myopathy) by measuring muscle function (e.g., muscle strength) are disclosed.

公开(公告)号：US11753668B2

公开(公告)日：2023-09-12

申请号：US17591171

申请日：2022-02-02

Applicant: Biogen MA Inc.

Inventor： Fernie Mitchelson ,  Erik Hughes ,  Jessica Mondia ,  Robin Parish Hyde-Deruyscher

IPC: C12P21/00 ,  C12N5/00 ,  C07K16/28

CPC classification number: C12P21/005 ,  C07K16/2839 ,  C12N5/0018 ,  C07K2317/14 ,  C07K2317/40 ,  C07K2317/41 ,  C12N2500/10 ,  C12N2500/20 ,  C12N2511/00 ,  C12N2513/00

Abstract: The present invention pertains to a cell culture medium comprising copper as a media supplement, which was shown to control recombinant protein glycosylation and methods of sing thereof. The present invention further pertains to a method of controlling or manipulating glycosylation of a recombinant protein of interest in a large scale cell culture.

公开(公告)号：US11655289B2

公开(公告)日：2023-05-23

申请号：US16639338

申请日：2018-08-22

Applicant: Biogen MA Inc.

Inventor： Steven Andrew Lantz ,  Kapil Gupta ,  Shantanu Sule ,  Adnan Zunic

IPC: A61K39/395 ,  C07K16/18 ,  A61K47/18 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61K39/00

CPC classification number: C07K16/18 ,  A61K39/3955 ,  A61K39/39591 ,  A61K47/183 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61K2039/505 ,  C07K2317/565 ,  C07K2317/94

Abstract: Pharmaceutical compositions containing anti-beta amyloid (Aβ) antibodies or AD-binding fragments thereof are provided. These pharmaceutical compositions find use in the treatment of abnormal accumulation or deposition of Aβ in the central nervous system, mild cognitive impairment, and AD-associated disorders such as Alzheimer's disease.